Survival benefit in critically ill burned patients receiving selective decontamination of the digestive tract: a randomized, placebo-controlled, double-blind trial.
OBJECTIVE
To evaluate whether selective digestive decontamination (SDD) reduces mortality from any cause, and the incidence of pneumonia among patients with severe burns.


BACKGROUND
SDD is a prophylactic strategy to reduce infectious morbidity and mortality in critically ill patients. Two meta-analyses and a recent randomized controlled trial demonstrated a mortality reduction varying between 20% and 40%. But this technique has never been properly evaluated in severely burned patients.


METHODS
The design of this single-center trial was randomized, double blind, placebo controlled. Patients with burns > or =20% of total body surface and/or suspected inhalation injury were enrolled and assigned to receive SDD or placebo for the total duration of treatment in the burn intensive care unit (ICU).


RESULTS
One hundred seventeen patients were randomized and 107 were analyzed (53 in the SDD group and 54 in the placebo group). The ICU mortality was 27.8% in the placebo group and 9.4% in the SDD group in the burn ICU. Treatment with SDD was associated with a significant reduction in mortality both in the burn ICU (risk ratio 0.25; 95% CI 0.08 to 0.76) and in the hospital (risk ratio 0.28; 95% CI 0.10 to 0.80), following adjustment for predicted mortality. The incidence of pneumonia was significantly higher in the placebo group: 30.8 and 17.0 pneumonias per 1000 ventilation days (P = 0.03) in placebo and SDD group, respectively.


CONCLUSIONS
Treatment with SDD reduces mortality and pneumonia incidence in patients with severe burns.
de La Cal
Miguel A
MA
Department of Critical Care Medicine, Hospital Universitario de Getafe, Madrid, Spain. mcal@ucigetafe.com
Cerdá
Enrique
E
García-Hierro
Paloma
P
van Saene
Hendrick K F
HK
Gómez-Santos
Dulce
D
Negro
Eva
E
Lorente
José Angel
JA
D000328:Adult; D000900:Anti-Bacterial Agents; D002056:Burns / Q000382:microbiology* / Q000401:mortality / Q000628:therapy; D016638:Critical Illness; D003428:Cross Infection / Q000517:prevention & control; D003666:Decontamination; D004311:Double-Blind Method; D004359:Drug Therapy, Combination / Q000008:administration & dosage*; D005260:Female; D041981:Gastrointestinal Tract / Q000382:microbiology*; D006801:Humans; D007362:Intensive Care Units; D008297:Male; D008875:Middle Aged; D018410:Pneumonia, Bacterial / Q000517:prevention & control; D018805:Sepsis / Q000517:prevention & control; D015996:Survival Rate; D014552:Urinary Tract Infections / Q000517:prevention & control
D000900:Anti-Bacterial Agents
Surgery. 1978 May;83(5):523-7
347612
Intensive Care Med. 1996 May;22(5):387-94
8796388
Crit Care Med. 1997 Jan;25(1):63-71
8989178
Ann Surg. 1987 Jan;205(1):82-7
3800465
Lancet. 1992 Jul 4;340(8810):5-9
1351620
N Engl J Med. 1998 Feb 5;338(6):362-6
9449729
Am J Respir Crit Care Med. 1994 Aug;150(2):565-9
8049849
J Antimicrob Chemother. 1994 Jul;34(1):139-48
7961200
Lancet. 2003 Sep 27;362(9389):1011-6
14522530
J Hosp Infect. 1996 May;33(1):1-12
8738198
J Trauma. 1994 Oct;37(4):655-9
7932899
Burns. 2001 Aug;27(5):439-45
11451595
Crit Care Med. 1990 Mar;18(3):264-9
2302949
Chest. 2001 Apr;119(4):1160-5
11296184
J Trauma. 1992 May;32(5):570-5
1588644
N Engl J Med. 1992 Feb 27;326(9):594-9
1734249
Clin Infect Dis. 1995 Apr;20(4):861-7
7795086
J Burn Care Rehabil. 1998 Sep-Oct;19(5):386-9
9789171
J Hosp Infect. 2004 Mar;56(3):175-83
15003664
Am J Infect Control. 1988 Jun;16(3):128-40
2841893
Am J Infect Control. 2002 Nov;30(7):391-9
12410215
J Burn Care Rehabil. 1990 Nov-Dec;11(6):575-80
2286616
Arch Surg. 1999 Feb;134(2):170-6
10025458
Chest. 1997 Mar;111(3):676-85
9118708
Burns. 2003 Feb;29(1):15-24
12543040
Am J Respir Crit Care Med. 2000 Jul;162(1):119-25
10903230
Ann Intern Med. 1994 Mar 1;120(5):389-95
8304656
J Trauma. 1997 Apr;42(4):687-94
9137259
Clin Plast Surg. 1974 Oct;1(4):693-703
4609676
Cochrane Database Syst Rev. 2004;(1):CD000022
14973945